Allergen-specific intralymphatic immunotherapy in human and animal studies
10.5415/apallergy.2017.7.3.131
- Author:
Seon Tae KIM
1
;
So Hyun PARK
;
Sang Min LEE
;
Sang Pyo LEE
Author Information
1. Department of Otolaryngology-Head and Neck Surgery, Gachon University Gil Medical Center, Incheon 21565, Korea.
- Publication Type:Review
- Keywords:
Immunotherapy;
Injections, intralymphatic;
Treatment efficacy;
Adverse effects
- MeSH:
Animals;
Humans;
Hypersensitivity;
Immunotherapy;
Injections, Intralymphatic;
Sublingual Immunotherapy;
Treatment Outcome
- From:
Asia Pacific Allergy
2017;7(3):131-137
- CountryRepublic of Korea
- Language:English
-
Abstract:
Clinical trials of intralymphatic immunotherapy (ILIT) have been performed to overcome the limitations of long-term therapy and the local or systemic hypersensitivity reactions in conventional allergen-specific immunotherapy, including subcutaneous or sublingual immunotherapy. Additionally, several animal studies of ILIT have been conducted in the form of translational or veterinary research. We conducted a literature review to examine the treatment efficacy and adverse effects of ILIT.
